The American Journal of Digestive Diseases

, Volume 4, Issue 4, pp 297–305 | Cite as

Hepatitis associated with iproniazid (Marsilid®)

Report of 3 cases
  • Herbert G. Levin
  • J. Edward Berk
  • Lloyd J. Paul
  • Charles Berman


The case histories of 3 patients who developed hepatitis with jaundice while taking iproniazid have been described. It is suggested that it might be wiser for the present not to use the drug in any patient with liver disease or impaired hepatic function. It is also recommended that the dose of the drug be reduced as rapidly as possible to the lowest level consistent with adequate clinical maintenance and that it be used for the shortest time possible.


Public Health Hepatitis Liver Disease Case History Hepatic Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Selikoff, I. J., Robitzek, E. H., andOrnstein, G. G. Treatment of pulmonary tuberculosis with hydrazide derivatives of isonicotinic acid.J.A.M.A. 150:973, 1952.Google Scholar
  2. 2.
    Bloch, R. G.,et al. The Clinical effect of isoniazid and iproniazid in the treatment of pulmonary tuberculosis.Ann. Int. Med. 40:881, 1954.PubMedGoogle Scholar
  3. 3.
    Bosworth, D. M.,et al. The use of iproniazid in the treatment of bone and joint tuberculosis.J. Bone & Joint Surg. 35:577, 1953.Google Scholar
  4. 4.
    Bosworth, D. M.,et al. Use of iproniazid in non-tuberculous bone and joint infections.J.A.M.A. 157:132, 1955.Google Scholar
  5. 5.
    Scherbel, A. L.: The effect of isoniazid and iproniazid in patients with rheumatoid arthritis.Cleveland Clin. Quart. 24:90, 1957.PubMedGoogle Scholar
  6. 6.
    de Verteuil, R. L., andLehmann, H. E. Therapeutic trial of iproniazid (Marsilid) in depressed and apathetic patients.Canad. M. A. J. 78:131, 1958.Google Scholar
  7. 7.
    Zetzel, L., andKaplan, H. Liver damage concurrent with iproniazid administration.New England J. Med. 258:1209, 1958.Google Scholar
  8. 8.
    Frantz, A. G. Fatal jaundice associated with iproniazid (Marsilid) therapy.J.A.M.A. 167:987, 1958.Google Scholar
  9. 9.
    Zeller, E. A., andBarsky, J. In vivo inhibition of liver and brain monoamine oxidase by 1-isonicotinyl-2-isopropyl hydrazine.Proc. Soc. Exper. Biol. & Med. 81:459, 1952.Google Scholar
  10. 10.
    Spector, S.,et al. Effect of iproniazid on brain levels of norepinephrine and serotonin.Science 127:704, 1958.Google Scholar
  11. 11.
    Arias, I. M., andZamcheck, N. Recent developments in the understanding of chlorpromazine jaundice.Am. J. Gastroenterol. 28:371, 1957.PubMedGoogle Scholar
  12. 12.
    Popper, H. Anatomy of the intraphepatic biliary system and the pathogenesis of intrahepatic cholestatic jaundice.Gastroenterology 34:1028, 1958.Google Scholar

Copyright information

© Paul B. Hoeber, Inc. 1959

Authors and Affiliations

  • Herbert G. Levin
    • 1
  • J. Edward Berk
    • 1
  • Lloyd J. Paul
    • 1
  • Charles Berman
    • 1
  1. 1.From the Departments of MedicineSinai Hospital of Detroit and Wayne State University College of MedicineDetroit

Personalised recommendations